Production (Stage)
Galera Therapeutics, Inc.
GRTX
$0.0326
$0.005118.55%
OTC PK
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 10.32% | -50.71% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 20.95% | -56.65% | |||
| Operating Income | -20.95% | 56.65% | |||
| Income Before Tax | 67.71% | 14.75% | |||
| Income Tax Expenses | -- | 100.00% | |||
| Earnings from Continuing Operations | 67.71% | 11.65% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 67.71% | 11.65% | |||
| EBIT | -20.95% | 56.65% | |||
| EBITDA | -20.64% | 56.59% | |||
| EPS Basic | 81.82% | 13.16% | |||
| Normalized Basic EPS | 17.89% | 70.43% | |||
| EPS Diluted | 81.82% | 13.16% | |||
| Normalized Diluted EPS | 17.89% | 70.43% | |||
| Average Basic Shares Outstanding | 77.94% | 1.77% | |||
| Average Diluted Shares Outstanding | 77.94% | 1.77% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||